These data clearly suggest that decreased expression of NF1 is partially caused by increased expression of miR‐641 in erlotinib‐resistant NSCLC, and NF1 is a key downstream effector that mediates the effects of miR‐641 on NSCLC cell erlotinib sensitivity. Here, NF1 is linked to non-small cell lung carcinoma.